Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis

Orphanet Journal of Rare Diseases

Volumn 10, Issue 1, 2015, Pages

  Denniston, Alastair K ^a,b   Holland, Gary N ^c   Kidess, Andrej ^a   Nussenblatt, Robert B ^d   Okada, Annabelle A ^e   Rosenbaum, James T ^f   Dick, Andrew D ^g,h,i  

^a Birmingham Women s Hospital NHS Foundation Trust   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c JULES STEIN EYE INSTITUTE   (United States)

^d NATIONAL EYE INSTITUTE   (United States)

^e KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g BRISTOL EYE HOSPITAL   (United Kingdom)

^h UNIVERSITY OF BRISTOL   (United Kingdom)

ⁱ MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Clinical trials; Composite endpoints; Endpoints; Outcome measures; Uveitis

Indexed keywords

CAPSULE OPACIFICATION; CAS REGISTRY; CHOROID DISEASE; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; CONTRAST SENSITIVITY; DISEASE ACTIVITY; EYE INFLAMMATION; HUMAN; INTERVENTION STUDY; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; MACULAR EDEMA; OUTCOME ASSESSMENT; PHENOTYPE; PREVALENCE; QUESTIONNAIRE; READING; REGISTER; REVIEW; SYSTEMATIC REVIEW; UVEITIS; VISION; VISUAL ACUITY; VISUAL ACUITY CHART; VISUAL FIELD; CLASSIFICATION;

CLINICAL TRIALS AS TOPIC; HUMANS; UVEITIS;

EID: 84939230877     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-015-0318-6     Document Type: Review

References (37)

1. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218(4):223-36.
2. Williams GJ, Brannan S, Forrester JV, Gavin MP, Paterson-Brown SP, Purdie AT, et al. The prevalence of sight-threatening uveitis in Scotland. Br J Ophthalmol. 2007;91(1):33-6.
3. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332-6.
4. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California;the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491-500.
5. Vadot E, Barth E, Billet P. Epdemiology of uveitis- preliminary results of a prospective study in Savoy. In: Saari K, editor. Uveitis update. Amsterdam: Elsevier; 1984. p. 13-6.
6. Jones NP. The Manchester Uveitis Clinic: The First 3000 Patients-Epidemiology and Casemix. Ocul Immunol Inflamm. 2013 Dec 2. [Epub ahead of print] PubMed PMID: 24295124.
7. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-16.
8. Denniston AK, Dick AD. Systemic therapies for inflammatory eye disease: past, present and future. BMC Ophthalmol. 2013;13:18. doi: 10.1186/1471-2415-13-18.
9. Sreekantam S, Denniston AK, Murray PI. Survey of expert practice and perceptions of the supporting clinical evidence for the management of uveitis-related cataract and cystoid macular oedema. Ocul Immunol Inflamm. 2011;19(5):353-7. doi: 10.3109/09273948.2011.592260.
10. Lowder C, Belfort Jr R, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Ozurdex HURON Study Group. Dexamethasone intravitrealimplant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545-53. doi: 10.1001/archophthalmol.2010.339.
11. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10):1916-26. doi: 10.1016/j.ophtha.2011.07.027.
12. Friedman DS, Holbrook JT, Ansari H, Alexander J, Burke A, Reed SB, et al. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology. 2013;120(8):1571-9. doi: 10.1016/j.ophtha.2013.01.025.
13. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467-71.
14. Kempen JH, Ganesh SK, Sangwan VS, Rathinam SR. Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Am J Ophthalmol. 2008;146(6):813-8. doi: 10.1016/j.ajo.2008.06.004. Epub 2008 Aug 8. PubMed.
15. Hornbeak DM, Payal A, Pistilli M, Biswas J, Ganesh SK, Gupta V, et al. Interobserver Agreement in Clinical Grading of Vitreous Haze Using Alternative Grading Scales. Ophthalmology. 2014. doi: 10.1016/j.ophtha.2014.02.018.
16. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet. 2014;383(9913):257-66. doi: 10.1016/S0140-6736(13)62296-5. Epub 2014 Jan 8. PubMed PMID: 24411650.
17. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903-12. PubMed.
18. Schulz KF, Altman DG, Moher D, for the CONSORT Group.CONSORT Checklist. Available at http://www.consort-statement.org/checklists/view/32-consort/80-outcomes. [Last accessed 16 March 2015]
19. Sugar EA, Jabs DA, Altaweel MM, Lightman S, Acharya N, Vitale AT, et al. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol. 2011;152(6):1044-52. doi: 10.1016/j.ajo.2011.05.028. e5.
20. Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci. 2011;52(5):2741-8. doi: 10.1167/iovs.09-4493.
21. Taylor SR, Lightman SL, Sugar EA, Jaffe GJ, Freeman WR, Altaweel MM, et al. The impact of macular edema on visual function in intermediate, posterior, and panuveitis. Ocul Immunol Inflamm. 2012;20(3):171-81. doi: 10.3109/09273948.2012.658467.
22. Hee MR, Puliafito CA, Wong C, Duker JS, Reichel E, Rutledge B, et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol. 1995;113(8):1019-29.
23. Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, Iliev ME, Frey M, Rothenbuehler SP, et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci. 2009;50(7):3432-7.
24. Keane PA, Karampelas M, Sim DA, FRCOphth, Sadda S, Tufail A, Sen HN, Nussenblatt RB, Dick AD, Lee RW, Murray PI, Pavesio CE, Denniston AK. Objective Measurement of Vitreous Inflammation using Optical Coherence Tomography Ophthalmology 2014 May 15. doi: 10.1016/j.ophtha.2014.03.006
25. Kiss CG, Barisani-Asenbauer T, Maca S, Richter-Mueksch S, Radner W. Reading performance of patients with uveitis-associated cystoid macular edema. Am J Ophthalmol. 2006;142(4):620-4.
26. Munk M, Kiss C, Huf W, Sulzbacher F, Bolz M, Sayegh R, et al. Therapeutic interventions for macular diseases show characteristic effects on near and distance visual function. Retina. 2013;33(9):1915-22.
27. Denniston AK, Kyte D, Calvert M, Burr JM. An introduction to patient-reported outcome measures in ophthalmic research. Eye (Lond). 2014;28(6):637-45.
28. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-list-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050-8.
29. Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. Arch Ophthalmol. 2001;119(6):841-9.
30. Murphy CC, Greiner K, Plskova J, Frost NA, Forrester JV, Dick AD. Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. Br J Ophthalmol. 2007;91(2):154-6.
31. Frick KD, Drye LT, Kempen JH, Dunn JP, Holland GN, Latkany P, et al. Multicenter Uveitis Steroid Treatment-MUST Trial Research Group. Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial. Invest Ophthalmol Vis Sci. 2012;53(3):1169-76.
32. Naik RK, Rentz AM, Foster CS, Lightman S, Belfort Jr R, Lowder C, et al. Normative comparison of patient-reported outcomes in patients with noninfectious uveitis. JAMA Ophthalmol. 2013;131(2):219-25.
33. Lightman S, Belfort Jr R, Naik RK, Lowder C, Foster CS, Rentz AM, et al. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterioruveitis. Invest Ophthalmol Vis Sci. 2013;54(7):4864-70.
34. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ. 1998;317:1181-4.
35. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13:132. doi: 10.1186/1745-6215-13-132.
36. Core Outcome Measure in Effectiveness Trials Initiative. Available at http://www.comet-initiative.org [Last accessed 16 March 2015].
37. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available at http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf [Last accessed 16 March 2015].